| Summary of Segment Reconciliation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
(in thousands) |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
|
Salaries and staff costs |
|
$ |
2,134 |
|
|
$ |
1,714 |
|
|
$ |
4,103 |
|
|
$ |
3,582 |
|
Stock-based compensation |
|
|
672 |
|
|
|
397 |
|
|
|
1,187 |
|
|
|
786 |
|
Clinical trials, outside services, and lab supplies |
|
|
8,306 |
|
|
|
6,950 |
|
|
|
15,803 |
|
|
|
12,202 |
|
Facilities and other |
|
|
468 |
|
|
|
432 |
|
|
|
964 |
|
|
|
931 |
|
Total research and development |
|
$ |
11,580 |
|
|
$ |
9,493 |
|
|
$ |
22,057 |
|
|
$ |
17,501 |
|
Selling, general and administrative: |
|
|
|
|
|
|
|
|
|
|
|
|
Salaries and staff costs |
|
$ |
849 |
|
|
$ |
807 |
|
|
$ |
1,775 |
|
|
$ |
1,714 |
|
Stock-based compensation |
|
|
1,011 |
|
|
|
782 |
|
|
|
1,861 |
|
|
|
1,517 |
|
Outside services and professional fees |
|
|
1,062 |
|
|
|
1,167 |
|
|
|
2,860 |
|
|
|
2,150 |
|
Facilities and other |
|
|
396 |
|
|
|
459 |
|
|
|
836 |
|
|
|
964 |
|
Total selling, general and administrative |
|
$ |
3,318 |
|
|
$ |
3,215 |
|
|
$ |
7,332 |
|
|
$ |
6,345 |
|
|
| Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share |
The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
|
|
2025 |
|
|
2024 |
|
Options to purchase Common Stock |
|
|
11,701,432 |
|
|
|
8,351,122 |
|
Warrants to purchase Common Stock |
|
|
2,787,714 |
|
|
|
2,807,353 |
|
Series A Convertible Preferred Stock |
|
|
877 |
|
|
|
877 |
|
|
|
|
14,490,023 |
|
|
|
11,159,352 |
|
|